Pharmaceuticals

Global Oral Proteins And Peptides Market Forecast 2026–2035: Long-Term Growth Insights

February 17, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oral proteins and peptides market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Oral Proteins And Peptides Market show for the 2026–2030 period?

The oral proteins and peptides market size has experienced significant expansion in recent years. It is projected to grow from $1.56 billion in 2025 to $1.91 billion in 2026, at a compound annual growth rate (CAGR) of 22.5%. The market’s historical growth can be attributed to several factors, including the limited oral bioavailability of proteins and peptides, a reliance on injectable formulations, the growing prevalence of diabetes and gastrointestinal disorders, increasing research in peptide therapeutics, and regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market size is projected to undergo exponential growth in the coming years, with expectations to reach $4.26 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.2%. This anticipated growth during the forecast period is largely due to the creation of novel delivery technologies for oral proteins, the expansion of chronic disease management programs, an increasing adoption of personalized and combination therapies, rising healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Prominent trends observed in this period include the increasing uptake of oral insulin and other therapeutic peptides, advancements in personalized medicine and targeted oral protein therapies, a growing emphasis on treatments for gastrointestinal disorders, the expansion of oral protein formulations designed for diabetes and metabolic disorders, and progress in long-acting and combination oral protein products.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Drivers Are Shaping The Development Of The Oral Proteins And Peptides Market?

The expanding biopharmaceutical industry is anticipated to fuel the progression of the oral proteins and peptides market moving forward. This sector, a component of the wider pharmaceutical industry, focuses on the development, production, and commercialization of medications sourced from biological origins. The biopharmaceutical industry’s expansion is attributed to advancements in biotechnology, a rising demand for personalized medicine, an increase in chronic disease prevalence, and greater investment in research and development. Oral proteins and peptides utilized in biopharmaceuticals present an avenue for non-invasive delivery of treatments, leading to enhanced patient compliance and a reduced need for injections. They are effective in targeting specific diseases, demonstrating improved stability and absorption within the digestive system. For instance, data from October 2025, provided by the UK-based government statistics body, the Bioscience and Health Technology Sector, revealed that in 2023/2024, the UK life sciences industry encompassed 6,170 businesses distributed among 7,320 companies. These businesses collectively employed 359,600 people and generated a turnover of £146.9 ($169.69) billion. Thus, the burgeoning biopharmaceutical industry is indeed a primary driver behind the growth of the oral proteins and peptides market.

Which Segments Are Contributing To The Growth Of The Oral Proteins And Peptides Market?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Which Trends Are Influencing The Performance And Direction Of The Oral Proteins And Peptides Market?

Leading entities within the oral proteins and peptides market are prioritizing the development of innovative formulation technologies to bolster peptide stability, permeability, and bioavailability in oral dosage forms. These enhancements are designed to address persistent issues like enzymatic degradation and inadequate absorption within the gastrointestinal tract. A notable example is the new collaboration launched in August 2025 between BioMed X, a Germany-based biomedical research institute, and Novo Nordisk, a Denmark-based pharmaceutical company, aimed at accelerating the advancement of next-generation oral peptide delivery technologies. This partnership intends to investigate novel molecular strategies and delivery mechanisms, facilitating the creation of oral peptide therapeutics that are safe, effective, and convenient for patients. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s extensive experience in peptide-based medicines, the joint initiative strives to propel breakthrough oral drug delivery solutions forward and expand the therapeutic applicability of peptide medicines across various metabolic and chronic diseases.

Who Are The Major Companies Operating In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Oral Proteins And Peptides Market?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Proteins And Peptides Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795